CAS and Molecule.one Announce a Strategic Collaboration to Accelerate Drug Discovery
CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230811660528/en/
Leveraging their existing technologies and expertise, including Molecule.one’s proprietary generative deep learning models and synthesis planning platform with chemist-first UI, and CAS’ world-class chemical reactions content collection and deep industry knowledge, the two organizations will work together to enhance and develop solutions for efficient and innovative chemical synthesis planning. Beyond their complementary capabilities, the organizations’ collaboration is fueled by their shared goal to empower scientists and accelerate breakthroughs.
“We are thrilled to bring to market the first generative models for chemistry trained on CAS’ content, as CAS’ strategic partner for synthetic accessibility and retrosynthesis deep learning enhancements,” says Piotr Byrski, Molecule.one’s co-founder and CEO. “Generative AI has demonstrated amazing feats across multiple fields when trained on large datasets and I believe that there’s a clear need for bringing this to drug discovery. I’m very proud of both CAS & Molecule.one teams, who have worked diligently over the past year to identify how we can bring together Molecule.one’s unique technology and expertise in AI and CAS’ comprehensive chemical dataset. I am excited that in the upcoming months and years, we will witness the outcomes of this collaboration and the significant impact it will have on the pharmaceutical industry.”
The first joint offering, M1 RetroScore powered by CAS, will be part of the Molecule.one product suite and will replace their current synthetic accessibility scoring tool, RetroSAS. Leveraging the recent advances in generative model development by Molecule.one’s team, the solution uses machine learning models trained on the CAS best-in-class chemical reactions content to predict the likelihood of synthesis for novel molecules. M1 RetroScore powered by CAS provides all users with synthetic accessibility scores along with the corresponding potential top synthesis pathways for given targets. For users of CAS SciFindern, the tool will connect with reference reactions within the CAS SciFindern platform. M1 RetroScore powered by CAS is the first commercially available synthetic accessibility scoring tool trained on CAS content.
Molecule.one and CAS are also collaborating to enhance the world-class retrosynthesis capabilities already available in CAS SciFindern. As part of their continued dedication to improving their solutions, CAS will incorporate Molecule.one’s deep learning models to improve its synthesis predictions and aid scientists in exploring potential synthetic routes for small molecules, thus accelerating scientific breakthroughs.
“Chemical reactions and retrosynthesis capabilities from CAS are unparalleled,” says Tim Wahlberg, Chief Product Officer for CAS. “By collaborating with Molecule.one, we will bring a unique combination of capabilities to the market to solve challenges in synthesis planning – both early-stage screening for synthesizability as well as laboratory and scale-up synthesis design. These solutions will continue to reduce time spent in the discovery process for scientists, empowering them with efficiencies throughout their innovation journey.”
M1 RetroScore powered by CAS will officially launch on August 14 and will be presented at Molecule.one’s booth #364 at ACS Fall 2023 from August 14-16 in San Francisco. Learn more at www.molecule.one/retroscore.
CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at cas.org.
Molecule.one (M1) is a seed-stage tech-bio company developing cutting-edge AI-enabled chemical synthesis planning solutions to support early-stage drug discovery pipelines. M1’s interdisciplinary team of machine learning experts, software engineers and chemists, collaboratively develops solutions for analysis of synthetic accessibility, chemical reaction prediction, and reaction condition recommendations, leveraging advances in AI and proprietary data from Molecule.one’s own high-throughput laboratory. Their products are designed for chemists, by chemists. Molecule.one brought the first commercially available deep learning retrosynthesis planning solution to market in 2019 and has raised over $5 million USD to date.
Learn more at www.molecule.one.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Launches Online GIS Course for Climate Action28.9.2023 23:01:00 EEST | Press release
As the impacts of climate change increase and intensify around the world, one aspect that has become clear is the geographic nature of the issue. The ability to tackle such a wide-reaching geographic challenge requires technology that gives context, which location intelligence provides. To support the individuals working toward this goal, Esri, the global leader in geographic information system (GIS) technology, today announced it will offer a new massive open online course (MOOC) exploring the application of its software to address climate change impacts. The complimentary course will be available this fall for six weeks on the Esri Academy website and includes full access to ArcGIS Pro, ArcGIS Network Analyst, ArcGIS Online, and other ArcGIS software that uses science-based tools and authoritative data. GIS for Climate Action opens on October 25 and provides a comprehensive introduction to how GIS software is used to ingest, map, visualize, analyze, and share massive amounts of data.
Bartek Ingredients on Track with New Facility Doubling Capacity and Cutting Emissions by 80 Percent28.9.2023 22:43:00 EEST | Press release
Bartek Ingredients is pleased to provide an update on its progress on the world’s largest malic and fumaric acid manufacturing facility. The project, which broke ground in January 2023, is on schedule to deliver product to customers by the end of September 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928870100/en/ New Bartek manufacturing facility on track to deliver product by September 2024. (Photo: Business Wire) “We’re proud to confirm that we’re progressing as expected,” Bartek CEO John Burrows said. “We’re really excited to deliver our expanded capacity by next summer, in addition to new capabilities for a variety of new products.” Bartek expects the new facility to set a new global benchmark for plant safety, efficiency, and environmental performance. Among its anticipated accomplishments is a doubling of Bartek’s production capacity and a per unit greenhouse gas emissions reduction of more than 80 percent.
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.28.9.2023 17:30:00 EEST | Press release
Brenus Pharma announces that pre-clinical advancements of its inaugural research program were presented at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23) and will be showcased at the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1-5) These communications focus on pre-clinical validation of new developments of the first product generated by the STC Platform, STC-1010, which targets colorectal cancer in a first line of treatment. CONFERENCE TITLE AUTHORS RESULTS CICON23 P119: Allogenic Tumor Cell-Based Vaccine to Treat Colorectal Cancer: Development and Preclinical Validation George ALZEEB, Scientific Project Manager, Brenus Pharma, (Ph.D) Corinne TORTORELLI, Medical Lead, Brenus Pharma, (Pharm. D., Ph.D) Corentin RICHARD, Postdoc, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Romain BOIDOT, Molecular biologist, Centre Georges-François Leclerc, ICMUB UMR CNRS 6302, (PhD) Tangu
BM3EAC Corp. 2023 Semi-Annual Report28.9.2023 16:15:00 EEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2023 to 30 June 2023. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announ
ASM Global and Leading Finnish Development Company Suvilahden Areena Oy to Partner in Major Helsinki Entertainment Venue Exploration28.9.2023 16:00:00 EEST | Press release
ASM Global, the world’s largest producer of entertainment experiences, and Suvilahden Areena Oy have announced an unprecedented alliance to propose serving as the lead in the future reimagination of Helsinki’s sprawling iconic and historic Hanasaari power plant built in 1909. The duo’s aim is to preserve as much of the legendary landmark building while integrating local culture and environment in combination with a state-of-the-art arena and festival area within the development. ASM Global will anchor the music and live-entertainment venue while exploring incorporating sports programming on a major scale. ASM Global Europe President Chris Bray said, “Hanasaaren voimala is a major next step for ASM Global in Finland. We already have a strong presence in Scandinavia and are now building on our recent expansion into Helsinki, which includes Kulttuuritalo. We believe that with our unrivalled global network, we will bring the world’s most sought-after concerts and artists to fans in Helsink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom